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Abstract
Background: Expression of the HIV-1 vpr gene in human and fission yeast cells displays multiple
highly conserved activities, which include induction of cell cycle G2 arrest and cell death. We have
previously characterized a yeast heat shock protein 16 (Hsp16) that suppresses the Vpr activities
when it is overproduced in fission yeast. Similar suppressive effects were observed when the fission
yeast hsp16 gene was overexpressed in human cells or in the context of viral infection. In this study,
we further characterized molecular actions underlying the suppressive effect of Hsp16 on the Vpr
activities.
Results: We show that the suppressive effect of Hsp16 on Vpr-dependent viral replication in
proliferating T-lymphocytes is mediated through its C-terminal end. In addition, we show that
Hsp16 inhibits viral infection in macrophages in a dose-dependent manner. Mechanistically, Hsp16
suppresses Vpr activities in a way that resembles the cellular heat shock response. In particular,
Hsp16 activation is mediated by a heat shock factor (Hsf)-dependent mechanism. Interestingly, vpr
gene expression elicits a moderate increase of endogenous Hsp16 but prevents its elevation when
cells are grown under heat shock conditions that normally stimulate Hsp16 production. Similar
responsive to Vpr elevation of Hsp and counteraction of this elevation by Vpr were also observed
in our parallel mammalian studies. Since Hsf-mediated elevation of small Hsps occurs in all
eukaryotes, this finding suggests that the anti-Vpr activity of Hsps is a conserved feature of these
proteins.
Conclusion: These data suggest that fission yeast could be used as a model to further delineate
the potential dynamic and antagonistic interactions between HIV-1 Vpr and cellular heat shock
responses involving Hsps.
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Background
Human immunodeficiency virus type 1 (HIV-1) viral pro-
tein R (Vpr), a virion-associated protein with a calculated
molecular weight of 12.7 kilodalton (kD), is highly con-
served among HIV, simian immunodeficiency virus (SIV)
and other lentiviruses [1-3]. During the acute phase of the
viral infection, Vpr is preferentially targeted by the HIV-
specific CD8 T-lymphocytes [4,5]. Increasing evidence
suggests that Vpr plays an important role in the viral life
cycle and pathogenesis. For example, Vpr is required both
in vitro and in vivo for viral pathogenesis and efficient viral
infection of non-dividing host cells such as monocytes
and macrophages [6,7]. Rhesus monkeys, chimpanzees
and human subjects infected with Vpr-defective viruses
have a slower disease progression often accompanied by
reversion of the mutated vpr genes back to the wild type
phenotype [8-12].
Vpr displays several distinct activities in host cells. These
include induction of cell cycle G2 arrest [13-17] and cell
killing [18]. The cell cycle G2 arrest induced by Vpr is
thought to suppress human immune functions by pre-
venting T cell clonal expansion [19] and to provide an
optimized cellular environment for maximal levels of
viral replication [8]. In addition, Vpr induces cell death,
which may contribute to the depletion of CD4+ T-cells in
HIV-infected patients [12,18]. Whether Vpr-induced G2
arrest and cell death are functionally independent of each
other is currently of controversial. There are reports sug-
gested that these two activities are separable both in fis-
sion yeast and mammalian cells [20-24]; others suggested
that Vpr-induced apoptosis is cell cycle dependent
[25,26]. Reasons for these discrepancies are not clear at
the moment. In an earlier report, we demonstrated that
overexpression of fission yeast (Schizosaccharomyces
pombe) Hsp16 specifically suppresses Vpr activities, resem-
bling cellular stress responses to heat shock, [27]. Here,
we further show that this suppression is mediated by a
heat shock factor (Hsf)-mediated mechanism. Further-
more, we have also tested the suppressive effect of Hsp16
on wild type and a F34I mutant Vpr. The wild type Vpr
induces cell cycle G2 arrest and cell death, the F34IVpr
mutant is incapable of inducing cell death but retains its
ability to induce cell cycle G2 arrest both in fission yeast
[21,27,28] and mammalian cells ([29]; our unpublished
data) Thus, examination of the wild type and the F34I
mutant Vpr enable us to investigate these two Vpr activi-
ties separately. In addition, the highly conserved Vpr effect
on cell cycle G2/M regulation and cell survival makes fis-
sion yeast a particularly useful model to study mecha-
nisms of these Vpr activities (For review of this subject, see
[30-34]). Interestingly, vpr gene expression appears to trig-
ger a moderate increase in Hsp16 levels but counteracts
heat shock-mediated elevation of Hsp16. Together, our
findings suggest a highly conserved and dynamic inter-
play between vpr gene expression and cellular heat shock
response involving heat shock proteins.
Results
Endogenous Hsp16 is responsive to vpr gene expression
We previously identified fission yeast Hsp16 as a potent
Vpr suppressor [27]. Analysis of hsp16 expression in S.
pombe Q1649 strain, in which the hsp16 gene is tagged
with GFP and is under the control of its native promoter
[35], demonstrated that both the wild type Vpr and the
mutant protein (Vpr') elicited Hsp16 production (Fig.
1A). The mutant Vpr', in which phenylalanine in position
34 was replaced with isoleucine (F34IVpr), was used in
this study to measure Vpr-induced cell cycle G2 induction
because the wild type Vpr kills cells. Vpr' has lost its ability
to induce cell killing but retains its capacity to induce G2
arrest as previously shown both in human (our unpub-
lished data) and yeast cells [21,27,28].
We next tested whether the expression of endogenous
hsp16 is responsive to vpr gene expression. Both the wild
type  vpr  and F34I mutant vpr  genes were induced by
depleting thiamine from the EMM medium as previously
described [36,37]. As shown in Fig. 1B, expression of wild
type vpr or mutant vpr' under normal growth conditions
elicited a moderate increase of the Hsp16 protein level
(Fig. 1B, lanes 3 and 5). The faint protein band in lane 2
could possibly be due to low level of vpr expression even
when the inducible promoter is repressed [36]. Together,
these observations suggest that Hsp16 production is
responsive to vpr gene expression. These results are con-
sistent with our studies in mammalian cells where vpr
gene expression stimulates expression of HSP27, a human
paralogue of Hsp16 (Our unpublished data).
Overproduction of Hsp16 suppresses viral infection in 
CD4-positive T-cells and macrophages
Vpr activities have been implicated as positive factors for
HIV-1 replication [6,8,38]. Consistent with these activi-
ties, Vpr has been shown to increase viral replication 2 to
4 fold in proliferating T lymphocytes [8,39,40] but its
activities are required for viral infection in non-dividing
cells such as macrophages [6,7]. Responsive expression of
human HSP27 and yeast hsp16 to Vpr suggest a possible
and highly conserved cellular activity against Vpr. Indeed,
we have showed previously that overproduction of Hsp16
reduces viral replication in CD4-positive T-cells in a Vpr-
dependent manner [27].
To further delineate the suppressive effect of Hsp16 on
Vpr, here we tested the effect of Hsp16 on viral replication
in CD4-postive cells infected by a viral strain IIIB, in
which the vpr gene has a frame shift mutation at codon 73
resulting in a truncated Vpr protein that misses 24 a.a. at
its C-terminus [8,11,41]. The C-terminal Vpr is responsi-Retrovirology 2007, 4:16 http://www.retrovirology.com/content/4/1/16
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ble for a number of Vpr activities including protein dimer-
ization [42], cell cycle G2 arrest and cell death [20,43]. We
established a CD4+ H9 cell line stably producing high
level of yeast Hsp16 (Fig. 2A). These H9 cells were then
infected with a HIV-1 Vpr-positive laboratory strain LAI.
To test the potential effect of Hsp16 on viral replication,
p24 antigen was measured in culture supernatants over a
period of 21 days after infection. As shown in Fig. 2B and
consistent with our previous findings [27], a consistent
but moderate reduction of HIV-1 viral replication was
observed in cells expressing hsp16. For example, levels of
p24 antigen steadily increased in HIV-infected cells
expressing the vector control from day 3 to day 21 of HIV-
1 infection indicating successful viral infection. (Fig. 2B-
a). However, a 1.5 to 4.5-fold reduction in p24 antigen
levels was detected in HIV-infected cells expressing Hsp16
from day 10 to 21 after viral infection. No detectable p24
antigen was observed in mock-infected cell over the entire
experimental period. To ensure the observed viral inhibi-
tion by Hsp16 is not cell line-specific, we examined
another CD4-positive cell line, CEM-SS, which was also
derived from T lymphocytes [44]. A similar suppressive
Endogenous Hsp16 is responsive to vpr gene expression Figure 1
Endogenous Hsp16 is responsive to vpr gene expression.    (A) Expression of hsp16 was measured through GFP green 
fluorescence as shown by gfp-hsp16 fusion protein expression.  Cells were grown under normal growth conditions and expres-
sion of the wild type vpr (Vpr) or mutant F34I vpr (Vpr’) was induced in thiamine depleted EMM medium as previously 
described [35].  Photographs were taken 24 hrs after gene induction.  Small panel in A-a shows cells without green fluores-
cence.  (B) Comparison of the Hsp16 protein levels in the presence and absence of Vpr as shown by Western blot analysis.  
The vpr or vpr’-expressing cells were collected at the same time as in panel (A).  Lane 1 shows wild type SP223 cells without 
plasmid; lanes 2 and 4 show cells with vpr gene expression repressed; lanes 3 and 5 – cells with vpr gene expression induced.  
Note that elevation of Hsp16 shown in lane 2 is most likely due to leakage of nmt1 promoter and low level gene expression 
under these conditions [36].  LC, protein loading control.  A protein band that nonspecifically reacted to the antibody was used 
as a protein loading control. GI, gene induction.  
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effect on viral replication (1.5 to 3.1-fold reduction) was
also observed in the CEM-SS cells that stably express hsp16
genes (Fig. 2B–c).
To examine whether Hsp16 retains its suppressive effect
on viral replication when 24 aa of the C-terminal Vpr is
removed, we repeated the same infection experiments in
the H9 and CEM-SS cells using the C-terminal truncated
Vpr-carrying viral strain IIIB. As shown in Fig. 2B-b and
Fig. 2B–d, the kinetics of viral replication were essentially
indistinguishable between cells with or without Hsp16,
suggesting that Hsp16 has lost its inhibitory effect on viral
replication in the absence of C-terminal end of Vpr.
The above data suggest the suppressive effect of Hsp16 is
specific to Vpr. Since Vpr is required for viral infection in
non-dividing cells such as macrophages, we next tested
the potential effect of Hsp16 on HIV infection in macro-
phages. Purified fission yeast Hsp16 protein was added to
primary human macrophages infected with HIV-1ADA with
increasing concentration from 1, 5 to 10 μg/ml of cells.
Viral replication was followed 7 and 10 days after infec-
tion by measuring the reverse transcriptase (RT) activities
in culture supernatants. To avoid potential interference of
endotoxin that often presents in purified recombinant
proteins [45], purified Hsp16 was treated with 10 μg/ml
Polymyxin B (PMB)-agarose that was shown to efficiently
remove endotoxin [45]. As shown in Fig. 2C-a, infected
macrophages without removing endotoxin (-PMB)
almost completely eliminated viral replication at day 7
after infection; about 3.5 to 7-fold decrease of viral infec-
tion was observed at day 10 with 1 or 5 μg/ml of Hsp16.
No viral activity was detectable at 10 μg/ml level. After
removing the possible endotoxin from Hsp16, reduced
but still significant reduction of viral replication was
observed both at day 7 and day 10 after infection. 2.6 to
8.0-fold decrease of viral replication were seen at day 7
with 1.7 to 5.5-fold reduction of viral replication was
observed in day 10. These data suggest a dose-dependent
suppression of viral replication by Hsp16 in macrophage.
To ensure the observed effect was indeed due to Hsp16, as
a control, we also tested the potential effect of purified
HSP27. 10 μg/ml of HSP27 with the same level of PMB
(10 μg/ml) was added to HIV-1ADA-infected macrophages
the same way as we did for Hsp16. RT activities were
measured over time. As shown in Fig. 2C-b, no significant
differences were seen during the entire 24 days after infec-
tion. These data suggest a dose-dependent suppression of
viral replication by Hsp16 in macrophage. Together, these
data show that overproduction of Hsp16 specifically
inhibits HIV-1 infection possibly by targeting the Vpr acti-
vates.
Heat shock factor is the key regulator for the elevation of 
Hsp16 and heat shock-mediated suppression of Vpr
Overexpression of hsp16  by itself has no any obvious
effect on cell length or morphology [27,35]. However, our
earlier data showed that overexpression of hsp16 or high
temperature (36°C) suppressed Vpr-induced G2 arrest as
measured by cell elongation in fission yeast [27], indicat-
ing a potential and specific suppressive effect of Hsp16 on
Vpr. Since Hsp16 can be activated by host cellular stress
responses through heat shock factor (Hsf)-mediated path-
way, we next investigated the potential involvement of
heat shock factor (Hsf) in the heat shock-mediated sup-
pression of Vpr. There is only one Hsf in S. pombe. How-
ever, deletion of hsf1 is lethal in yeast [46], thus we were
unable to test the deletion effect of Hsf on the Vpr activi-
ties. Instead, we overexpressed the hsf1  gene from a
pART1-hsf1 plasmid where it is controlled by an exoge-
nous and constitutively expressing adh promoter. Since no
specific antibody against Hsf1 is available, we used Hsp16
as a marker for hsf1 expression [35]. As shown in Fig. 3A-
a, b, empty pART1 plasmid had no effect on Vpr'-induced
cell elongation. Cells were 17.7 ± 0.7 μm in length 30 hrs
after vpr gene induction [47]. Expression of hsf1 by itself
in S. pombe cells gave rise to slightly shorter (6.1 ± 0.1 μm)
than normal cells (7.1 ± 0.1 μm) (Fig. 3A-c). Significantly,
expression of hsf1 appeared to prevent Vpr'-induced cell
elongation. Cell length measurements for hsf1 and vpr'-
expressing cells had an average of 7.0 ± 0.1 μm, which is
indistinguishable from the normal cells without Vpr' and
elevated Hsf1 (7.1 ± 0.1 μm; Fig. 3A-d). Western blot anal-
ysis confirmed proper Vpr' protein production under the
inducible condition and the Hsf-mediated production of
Hsp16 in these cells (Fig. 3C, lane 3–4). Western blot
analysis further verified that vpr gene expression was not
affected by Hsf1 expression (Fig. 3C, lane 4 vs. lane 2).
These observations suggested that Hsf1 is probably the
major cellular factor that contributes to the anti-Vpr activ-
ities. To verify this finding, we further examined whether
heat shock treatment can induce additional shortening of
cells besides the suppressive Hsf1 effect. If additional cel-
lular factors are involved in suppressing Vpr' during the
cellular heat shock response, we would expect to see
shorter cell length than when Hsf is overexpressed alone.
The same experiment as described above was repeated at
elevated temperature (36°C). No additional shortening of
cells beyond the length observed with Hsf1 overexpres-
sion at normal temperature was seen when vpr-expressing
cells were grown at 36°C with overproduced Hsf1 (Fig.
3B). Together, results of these experiments suggest that
Hsf is the key cellular regulator of heat shock-mediated
suppression of the Vpr activities.Retrovirology 2007, 4:16 http://www.retrovirology.com/content/4/1/16
Page 5 of 14
(page number not for citation purposes)
Hsp16 suppresses HIV-1 replication in CD4+ T-lymphocytes and macrophages Figure 2
Hsp16 suppresses HIV-1 replication in CD4+ T-lymphocytes and macrophages. (A, B) Effect of Hsp16 on HIV-1 
replication in CD4+ T-lymphocytes.  (A) Western blot analysis shows level of Hsp16 in HIV-infected CD4+ H9 cells.  Lane 1, 
mock-infected H9 cells; lane 2, HIV-infected H9 cells carrying empty vector pcDNA3.1; lane 3, HIV-infected cells hsp16-
expressing plasmid.  Control, protein loading control.  (B) Suppression of HIV-1 viral replication by Hsp16 requires C-terminal 
end of Vpr.  3 x 106 to 5 x 106 of hsp16-expressing H9 or CEM-SS cells were either mock infected or infected with 2.0 x 103 
TCID50 of HIV-1LAI or IIIB.  Equal infection of the cells was further verified by measuring viral RNA levels 24 hr after viral 
inoculation.  Viral replication was determined by p24 antigen levels.  (C) Analysis of Hsp16 or HSP27 effects on HIV-1 replica-
tion in macrophages.  Increasing concentration (1, 5 or 10 μg/ml) of purified recombinant fission yeast Hsp16 or 100 μg/ml of 
recombinant human HSP27 protein was added to 1 x 106 primary human macrophages infected with HIV-1ADA.. Viral inocu-
lates were equalized according to reverse transcriptase (RT) activity (5 x 105 counts per minute/106 cells.  Viral replication was 
monitored 7 and 10 days after infection by measuring reverse transcriptase (RT) activity in culture supernatants.  To neutralize 
the effect of potential contamination with endotoxin [45], 10 μg/ml of Polymyxin B (PMB) was added [45].  Results are mean ± 
SE of triplicates.  
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Heat shock factor is responsible for Hsp16 elevation and heat shock-mediated suppression of the Vpr activities Figure 3
Heat shock factor is responsible for Hsp16 elevation and heat shock-mediated suppression of the Vpr activi-
ties. (A) Overexpression of hsf1 suppressed Vpr-induced G2 arrest. a, overexpression of hsf1 reduced Vpr’-induced cell elon-
gation back to normal size. Cell images were captured 30 hrs after gene induction.  b, overexpression of vpr or vpr’ suppressed 
Vpr-induced G2 arrest as measured by flow cytometric analysis.  The vpr-repressing (off) and vpr-expressing (on) cells were 
prepared as described previously [37].  Forty-eight hours after vpr gene induction, cells were collected for flow cytometric 
analysis.  (B) No additional reduction of Vpr-induced cell elongation was seen when hsf1-expressing cells were treated with 
high temperature (36°C).  Average and standard deviation of cell length was calculated based on three independent experi-
ments by counting a minimum 90 cells.  (C) Inducible expression of HIV-1 vpr’ and constitutive expression of hsf1 under normal 
(30°C) and high (36°C) temperature shown by Western blot analysis.  Proteins were extracted from cells cultured 30 hrs after 
gene induction (GI).  Because of the lack of an antibody against fission yeast anti-Hsf1 and our interest in monitoring Hsf1-
mediated Hsp16 elevation, Hsp16 protein production was used here as marker for Hsf1 activity [35].
A
C
GI: - + - -- + + +
Vpr’+pART1 Vpr’+hsf1 Vpr’+pART1 Vpr’+hsf1
1            2          3          4           5           6            7           8      
Hsp16
Vpr
Ctr
36oC 30oC
B
b
36oC
30oC
Vpr’
+
pART1
Vpr’
+
hsf1
Vpr’
+
hsf1
Vpr’
+
pART1
vpr-off vpr-on
7.1± 0.1
a b
6.1f0.1 
c
7.0±0.1 
d
7.1± 0.0 
e
7.2f0.1 
f
7.1f0.1 
g
7.2f 0.0 
h
17.1± 0.7
Vpr
+
pART1
Vpr’
+
pART1
C
e
l
l
 
C
o
u
n
t
s
vpr-off vpr-on
Channels (FL2-A)
0 20 40 60 80 100 120
Channels (FL2-A)
0 20 40 60 80 100 120
Channels (FL2-A)
0 20 40 60 80 100 120
Channels (FL2-A)
0 20 40 60 80 100 120
Channels (FL2-A)
0 20 40 60 80 100 120
Channels (FL2-A)
0 20 40 60 80 100 120
Channels (FL2-A)
0 20 40 60 80 100 120
Channels (FL2-A)
0 20 40 60 80 100 120
Vpr
+
hsf1
Vpr’
+
hsf1
DNA Content
G1 G2 G1G2
aRetrovirology 2007, 4:16 http://www.retrovirology.com/content/4/1/16
Page 7 of 14
(page number not for citation purposes)
Vpr counteracts Hsp16 elevation induced by heat 
treatment at the transcriptional level
Even though induction of cellular heat shock response by
heat treatment suppresses vpr'-induced cell cycle G2 delay,
surprisingly, the same heat treatment was not able to
block Vpr-induced cell death in RE007 cells which express
the wild type vpr (Fig. 4A-3, bottom plate). Inability of
colony formation at high temperature is not due to lack of
vpr expression because Western blot analysis showed that
heat treatment does not affect the Vpr protein level (Fig.
4B; [27]). Since heat treatment induces high levels of
Hsp16 [35] and artificial overproduction of Hsp16 sup-
presses Vpr-induced cell death at both temperatures (Fig.
4A-a and 4A-4, bottom), it was puzzling why heat treat-
ment only suppresses Vpr-induced G2 arrest but it does
not suppress Vpr-induced cell killing. One potential
explanation is that wild type Vpr may actually prevent
heat-induced elevation of Hsp16. To test this possibility,
we measured protein levels of Hsp16 in the presence and
absence of Vpr using different methods. One was to
observe the fluorescent signal emitted by the GFP-Hsp16
fusion protein in a S. pombe Q1649 strain, in which the
hsp16 gene is tagged with GFP and is under the control of
its native promoter (Fig. 5A; [35]). Changes in the Hsp16
protein level were further quantified by measuring fluo-
rescent intensity (FI) using a luminescence spectropho-
tometer [35,48,49]. In addition, Western blot analysis was
also carried out to measure endogenous Hsp16. Two heat
treatment methods were used to delineate the potential
effect of Vpr on the Hsp16 protein levels. Acute heat shock
(45°C for 15 min) was used to transiently activate Hsp16,
and the Vpr effect was measured 2 hrs after the heat shock.
As an alternative method, constant high temperature was
used for lasting elevation of Hsp16, and the effect of Vpr
on Hsp16 was measured 48 hrs after cell culturing at
36°C.
Under the normal growth conditions, Hsp16 protein
expression is typically very low or undetectable (FI = 0.1 ±
0.3; Fig. 5A-a; Fig. 5B-a,b, lane 1 [35]). When these cells
were subjected to an acute heat shock (45°C for 15 min),
a significant increase (FI = 5.9 ± 0.2) in the Hsp16 protein
level was observed 2 hr after heat shock in cells that either
had no vpr-containing plasmid (Fig. 5A-d; Fig. 5B-a, b,
lane 2) or vpr gene expression was suppressed (Fig. 5B-a,
lanes 3,5). In contrast, the level of Hsp16 (FI = 3.1 ± 0.6)
was markedly decreased when wild type vpr was expressed
under the same heat shock conditions (Fig. 5A-e; Fig. 5B-
a, lane 4). Similar Hsp16 elevation (Fig. 5A-g; Fig. 5B-b,
lane 2–4) was also observed in cells grown under constant
high temperature at 36°C. Consistent with the observa-
tion shown in acute heat shock experiment, Hsp16 pro-
tein level was diminished in the vpr-expressing cells
cultured at 36°C for 48 hrs (Fig. 5B-b, lane 5). Thus, wild
type Vpr indeed inhibited heat-mediated activation of
Hsp16. Interestingly, no obvious decrease of Hsp16 was
observed with the RE076 cells carrying a mutant Vpr' dur-
ing the early hours (23 hrs) of heat treatments (Fig. 5A-i;
Fig. 5B-a, lane 6).
However, after prolonged (48 hrs) incubation of vpr-
expressing cells at constant high temperature, both the
wild type and mutant Vpr were able to eliminate Hsp16
elevation (Fig. 5B-b, lane 5–6). Taken together, these
observations provide an explanation to our finding that
heat treatment suppresses the Vpr'-induced cell cycle
defect but does not protect against Vpr-induced cell killing
because the F34I mutation in Vpr' may have attenuated
the ability of Vpr to down-regulate Hsp16 thus allowing
elevated Hsp16 to suppress activity of Vpr'. Therefore,
wild type Vpr specifically counteracts activation of Hsp16
in response to vpr gene expression or heat treatment.
It is of interest to note that overexpression of hsp16 under
the control of an exogenous nmt1 promoter suppressed
Vpr-induced cell killing in the wild type cells (Fig. 4A-2
bottom panel; [27]) suggesting that the counteracting
effect of Vpr on Hsp16 is specifically targeted to the hsp16
promoter, i.e., occurs at the transcriptional level. Attempt-
ing to confirm this possibility, we further tested whether
overexpression of hsp16 under the same nmt1 promoter
was also capable of suppressing Vpr-induced cell death at
36°C when Vpr has the strongest counteracting effect on
Hsp16. As shown in the bottom panel of Fig. 4A-4, over-
production of Hsp16 was indeed capable of blocking Vpr-
induced cell death at both high (36°C) and normal
growth temperature (30°C). Therefore, Vpr counteracts
Hsp16 elevation induced by heat treatment most likely at
the transcriptional level.
Discussion
In this report, we provide evidence that Hsf1 is the main
regulator responsible for Hsp16 elevation and anti-Vpr
responses in fission yeast cells. The fact that Hsf1 is
responsible for Hsp16-mediated response to Vpr indicates
that the effect of Hsp16 on Vpr resembles the cellular heat
shock responses. Indeed, overexpression of hsf1  com-
pletely reduced Vpr'-induced cell cycle G2 arrest as shown
by reversion of the cell elongation (Fig. 3A-d vs. b), shift of
the cellular DNA content from G2 to G1 (Fig. 3A-b) and
additional heat treatment of hsf-expressing cells did not
significantly enhance the suppressive effect of Hsf1 on Vpr
(Fig. 3B-h vs. d).
Even though vpr gene expression triggers Hsp16 elevation,
Vpr appears to prevent further elevation induced by heat
treatment (Fig. 5A-e; Fig. 5B-a, lane 4; Fig. 5B-b, lane 5),
suggesting a counteracting effect of Vpr on heat stress-like
cellular response possibly through transcriptional regula-
tion of hsp16. This notion is supported by our observa-Retrovirology 2007, 4:16 http://www.retrovirology.com/content/4/1/16
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tions that induction of Hsp16 by heat treatment failed to
counteract Vpr-induced cell death (Fig. 4A-3, bottom
plate). However, overexpression of hsp16 under the con-
trol of an exogenous nmt1  promoter completely sup-
pressed Vpr-induced cell death under the same heat shock
conditions ([27]; Fig. 4A-4). Possible transcriptional
down-regulation of hsp16 by Vpr is further evidenced by
the results shown in Fig. 5A, in which a GFP reporter was
fused with the endogenous hsp16  promoter [35] and
expression of vpr eliminated the Hsp16 elevation (Fig. 5A-
e, h). Although the molecular mechanism underlying this
transcriptional suppression of hsp16  is unclear at the
moment, the fact that Hsf activates Hsps through binding
of the Hsp promoters [50] and overexpression of hsf1 or
hsp16 through an exogenous adh or nmt1 promoter allevi-
ates the Vpr activity (Fig. 3A; [27]) support the idea that
Vpr may affect expression of hsp16 through competition
with Hsf for control of hsp16 expression. One possible sce-
nario is that Vpr may inhibit Hsf1 that results in reduced
transcription of hsp16. Alternatively, since Vpr is a weak
transcriptional activator through binding to the transcrip-
tional factor Sp1 [51], it is also possible that Vpr may com-
pete with Hsf1 by binding to the Sp1 region of the hsp16
promoter. Obviously additional tests are needed to eluci-
date these possibilities. Interestingly, only the wild type
Vpr was able to inhibit Hsp16 at early hours (23 hrs) after
induction, as a single amino acid substitution from phe-
nylalanine to isoleucine at position 34 of Vpr attenuated
its ability to suppress the increase of Hsp16 after acute
heat shock (Fig. 5A-i vs. h; Fig. 5B, lane 6 vs. lane 4). In
fact, an even higher level of Hsp16 was observed. This is
presumably due to the inability of Vpr' to compete with
Hsf-mediated Hsp16 elevation. Thus, assuming that
expression of hsp16 is responsive to both the presence of
Vpr and heat shock treatment, this larger increase of
Hsp16 could be an additive effect. Since amino acid sub-
stitution at residue 34 of Vpr diminishes the ability of Vpr
to induce cell death but retains induction of G2 arrest
[20,28,29], a plausible possibility is that suppression of
Hsp16 and induction of cell death by Vpr share common
pathways.
It should be mentioned that whether Vpr-induced G2
arrest and cell death are two functionally independent
activities is still of debate. Earlier reports suggested that
these two activities are separable both in fission yeast and
Expression of hsp16 under exogenous nmt1 promoter rather than endogenous promoter suppresses Vpr-induced cell killing Figure 4
Expression of hsp16 under exogenous nmt1 promoter rather than endogenous promoter suppresses Vpr-
induced cell killing. (A) High temperature does not suppress Vpr-induced cell killing but expression of hsp16 through a for-
eign nmt1 promoter does.  Plates in the top row are fission yeast cells streaked on thiamine-containing (vpr-off) EMM plates; 
bottom row plates are the same as the top plates except no thiamine (vpr-on) was added.  Plates are shown after 3-5 days of 
incubation.  (B) Induction of cellular heat shock responses does not affect the protein levels of the wild type Vpr (RE007) as 
indicated by the Western blot analysis.  GI, gene induction.
B
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Down-regulation of Hsp16 activation by Vpr Figure 5
Down-regulation of Hsp16 activation by Vpr. (A) Expression of hsp16 monitored by GFP-Hsp16 fusion protein expres-
sion.  For heat shock treatment, vpr gene expression was first induced at 30ºC for 21 hours and then cultures were treated 
with acute heat shock (Acute HS) at 45ºC for 15 min (middle columns) or exposed to constant 36°C (right columns).  The 
level of Hsp16 expression was examined 2 hrs after the heat shock, i.e., 23 hrs after vpr gene induction (GI).  (B) Comparison 
of the Hsp16 protein levels between acute heat shock and constant heat treatment shown by Western blot analysis.  The 
hsp16-expressing vpr (RE007) and vpr’ (RE076) cells were collected at the same time as in (A), i.e., 23 hrs after vpr gene induc-
tion.  a, Hsp16 protein levels under acute heat shock conditions.  Acute heat shock (45ºC for 15 min) was used to transiently 
activate Hsp16, and the Vpr effect was measured 2 hrs after the heat shock.  b, Hsp16 protein levels under constant and pro-
longed high temperature at 36°C.  The effect of Vpr on Hsp16 was measured 48 hrs after cell culturing at 36ºC, which nor-
mally induces constant elevation of Hsp16.  Lane 1 shows wild type SP223 cells without plasmid (Cell Ctr); lane 2 shows SP223 
cells carrying an empty plasmid (Plasmid Ctr); Ctr, control; GI, gene induction, +, vpr-on; -, vpr-off.  LC, a protein band that 
non-specifically reacted to the antibody and was used as a protein loading control.
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mammalian cells [20-24][52]. However, recent reports
indicated Vpr-induced apoptosis is cell cycle dependent
[25,26]. Although reasons for these discrepancies are not
completely clear at the moment, it is noticed that apopto-
sis shown in the Andersen's study describes a late event as
cells were collected 48–72 hrs after viral infection [26].
Prolonged cell cycle G2 arrest results in apoptosis. Thus, it
is not surprising to find that apoptosis described in the
Andersen's study is ANT-independent and ANT-depend-
ent apoptosis was documented previously [53]. Addi-
tional difference between the apoptosis described by
Andersen et al from others is also noticed in the examina-
tion of two Vpr mutations. The R77Q and I74A mutants,
which separate the apoptosis and G2 arrest induced by
Vpr [24,54], showed no separation between the G2 induc-
tion and apoptosis. In our study, the F34IVpr mutant is
unable to induce cell death but retains its ability to induce
cell cycle G2 arrest both in fission yeast [21,27,28] and
mammalian cells ([29]; our unpublished data) It thus
allowed us to differentiate the effect of a wild type Vpr vs.
a mutant Vpr that only confers the inhibitory effect on cell
cycle regulation.
Responsive elevation of fission yeast Hsp16 and its
human paralogue HSP27 (our unpublished data) suggests
that the cellular heat stress-like responses might be antag-
onistic to Vpr. Indeed, we previously showed that overex-
pression of hsp16 and human HSP27 suppress the Vpr
activities, including cell cycle G2 arrest and cell killing,
both in fission yeast and human cells ([27]; our unpub-
lished data). However, the suppressive effect of yeast
Hsp16 and human HSP27 on Vpr are not identical. Over-
production of Hsp16 completely eliminated all of the Vpr
activities including the positive role of Vpr in supporting
viral replication in macrophages (Fig. 2C-a). Under the
same condition, however, HSP27 has no clear suppressing
effect against Vpr in macrophages (Fig. 2C-b). One possi-
ble difference between these two HSPs is that Hsp16 asso-
ciates directly with Vpr [27] but no clear HSP27-Vpr
interaction was detected both in vitro and in vivo (our
unpublished data). Unlike Hsp16, overexpression of
HSP27 is unable to block nuclear transport capacity of Vpr
(our unpublished data). Since nuclear transport of Vpr is
required for HIV-1 infection in non-dividing cells such as
macrophages [7,55,56], the inability of HSP27 to block
nuclear import of Vpr could potentially explain why it has
no effect on HIV-1 infection in macrophages.
There appears to be a dynamic interaction between vpr
gene expression and activation of Hsp16 in fission yeast.
Results of our parallel studies in mammalian cells indi-
cated a similar dynamic and antagonistic interaction
between Vpr and HSP27 (our unpublished data). This
finding is not surprising because activation of heat shock
proteins by Hsf1 is a highly conserved cellular process
among all eukaryotic cells [50]. All eukaryotes encode at
least one heat shock factor that is believed to regulate tran-
scription of heat shock genes. This protein binds to a reg-
ulatory sequence, i.e., the heat shock element, that is
absolutely conserved among eukaryotes [50]. Based on
the data presented, we hypothesize that expression of vpr
or HIV infection elicits a transient activation of the small
heat shock proteins (sHsps) of eukaryotes through an Hsf-
mediated pathway. Activation of these sHsps is most
likely a part of the cellular antiviral reaction to HIV infec-
tion and specifically to Vpr. However, these stress
responses are normally not sufficient to suppress the Vpr
activities because of active counteraction from Vpr.
Importantly, however, the Vpr activities could be com-
pletely blocked when sHsp's are produced under control
of an exogenous promoter thus avoiding transcriptional
inhibition by Vpr. Since the Vpr-specific activities have
been linked to such clinical manifestation of AIDS as acti-
vation of viral replication [57], suppression of host
immune responses [19] and depletion of CD4+ T-lym-
phocytes [12,58], this finding could potentially provide a
new approach to reducing Vpr-mediated detrimental
effects in HIV-infected patients by stimulating expression
of sHsps.
Methods
Maintenance and growth of mammalian and yeast cells
Genotypes and sources of S. pombe strains, mammalian
cell lines and plasmids used in this study are summarized
in Table 1. CD4-positive H9 and CEM-SS cells were grown
in RPMI 1640 medium supplemented with 10% heat-
inactivated fetal calf serum (FCS) and 100 unit/ml of pen-
icillin/streptomycin. Gene inductions of HIV-1 vpr and
other cellular genes under the control of the nmt1 pro-
moter in fission yeast have been described previously
[27,37]. Cells containing the plasmid with the nmt1 pro-
moter were first grown to stationary phase in the presence
of 20 μM thiamine. Cells were then washed three times
with distilled water, diluted to a final concentration of
approximately 2 × 105 cells/ml in 10 ml of the appropri-
ately supplemented EMM medium with or without thia-
mine. Cells were examined approximately 24 hours after
gene induction. Fission yeast cells were normally grown at
30°C with constant shaking at 250 rpm unless otherwise
specified.
Induction of cellular heat shock responses were con-
ducted as previously described [27,35,59]. Briefly, cul-
tures were first grown as mentioned above to fully express
vpr and then exposed to either an acute heat shock at 45°C
for 15 min or grown at consistent high temperature at
36°C for an indicated period of time.Retrovirology 2007, 4:16 http://www.retrovirology.com/content/4/1/16
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Measurement of the Vpr-specific activities in fission yeast
All of the functional assays used to measure Vpr-specific
activities, i.e. cell cycle G2 arrest and cell death induced by
Vpr, have been described previously [20,37,60]. Vpr-
induced G2 arrest can be specifically measured in fission
yeast based on a number of cellular endpoints [21,37].
Here we used F34IVpr (Vpr')-induced cell elongation as a
marker of G2 arrest [47,61]. The mutant Vpr', in which
phenylalanine was replaced with isoleucine in position 34
(F34IVpr) was used instead of the wild type Vpr because
Vpr' has lost its ability to induce cell killing but retains its
capacity to induce G2 arrest, as previously shown both in
human (our unpublished data) and fission yeast cells
[21,27,28]. The use of cell elongation, also known as "cdc
phenotype", as a marker for cell cycle G2/M delay is a
standard approach in fission yeast [47,61-63]. Cell images
were first captured on a Leica microscope and the cell
length was determined using OpenLab software. Average
and standard deviation of cell length were calculated
based on three independent experiments, each counting
at least 100 cells. To verify Vpr-induced cell cycle G2
arrest, flow cytometric analysis is carried out as previously
described [37]
Induction of cell death by Vpr was detected by inability of
vpr-expressing cells to form colonies on agar plates as pre-
viously described [60]. Briefly, S. pombe cells containing
the pYZ1N::vpr constructs were first grown on a selective
leucine-free minimal EMM plate under vpr-repressing
condition. A loopful of viable cells was streaked onto vpr-
inducing or vpr-repressing EMM plates and incubated at
30°C for 3–4 days. Inability to form colonies on the vpr-
inducing EMM plates but normal growth on the vpr-
repressing EMM plates is indicative of Vpr-induced cell
killing [20,64].
Viral infections
To evaluate the suppressive effect of Hsp16 on viral repli-
cation in proliferating CD4-positive T-lymphocytes, H9
and CEM-SS cells [41] that stably express a plasmid con-
trol or hsp16 were established [27]. 3 × 106 to 5 × 106 of
these H9 or CEM-SS cells were either mock infected or
infected with 2.0 × 103 TCID50 of HIV-1LAI or IIIB. The
HIV-1 LAI strain carries a wild type vpr gene; the vpr gene
in the IIIB strain has a frame shift mutation at codon 73,
which results in a truncated Vpr protein missing its C-ter-
minus [8,11,41]. Equal infection of the cells was further
verified by measuring viral RNA levels 24 hr after viral
inoculation using the Roche Monitor assay following the
manufacturer's instructions. Viral replication was deter-
mined by p24 antigen levels using a commercially availa-
ble HIVAG-1 polyclonal antigen kit (Abbott Laboratories,
Abbott Park, IL).
Monocyte-derived macrophages (MDMs) were prepared
from peripheral blood mononuclear cells (PBMCs) by
adherence to plastic as described previously [65]. Briefly,
human PBMCs were isolated from buffy coats of healthy
seronegative donors by Ficoll density gradient centrifuga-
tion (Ficoll-Paque PLUS; Pharmacia Biotech, Piscataway,
NJ). PBMCs were cultured in Primaria flasks (Becton Dick-
inson, Franklin Lakes, NJ) in culture medium (Dulbecco
modified Eagle medium [DMEM]) supplemented with
10% heat-inactivated normal human serum, 2 mM
glutamine, 50 U/mL penicillin, and 50 μg/mL streptomy-
cin (all from Life Technologies, Bethesda, MD) at 37°C in
a CO2 incubator at a cell density of 8 × 106 cells/mL. At 2
hours after plating, nonadherent cells were aspirated, and
the adherent cells were cultured overnight in DMEM sup-
plemented with macrophage colony-stimulating factor
(M-CSF, 2 ng/mL). At 18 hours after initial plating, adher-
ent cells were detached with 10 mM EDTA (ethylenedi-
aminetetraacetic acid)/phosphate-buffered saline (PBS)
and plated in 24-well Primaria plates (Becton Dickinson)
at a density of 106 cells/mL for 7 days in the presence of
recombinant human M-CSF (at 2 ng/mL). After 7 days,
final MDM cultures were composed of about 98% macro-
phages as judged by morphology and nonspecific esterase
activity. A macrophage-tropic HIV-1 strain ADA [66] was
used for infection of MDM. Cells were infected with viral
inoculae equalized according to the reverse transcriptase
(RT) activity (5 × 105 counts per minute/106 cells).
Fluorescence microscopy
A Leica fluorescence microscope DMR equipped with a
high performance CCD camera (Hamamatsu) and Open-
Lab software (Improvision, Inc., Lesington, MA) was used
for all imaging analyses. Fission yeast cells were collected
onto a regular glass slide and covered with cover slip. For
the observation of green fluorescent protein, we used a
Leica L5 filter, which has an excitation of 480/40 (460–
500 nm) and emission of 527/30 (512–542 nm). Induc-
tion of cellular heat shock responses were conducted as
previously described [35,59]. The level of hsp16  gene
expression was quantified by measuring fluorescent signal
emitted from the GFP-Hsp16 fusion protein as described
previously [35,48,49]. For DNA staining, cells were coun-
terstained with 1 μg/ml DAPI, which was observed with a
Leica A8 filter with an excitation of 360/40 (340–380 nm)
and emission of 470/40 (450–490 nm). Cell length was
measured individually on the captured images using the
OpenLab software. Statistical significance of differences in
cell length was determined using the t-test for paired sam-
ples.
Western blot analysis
For Western blot analysis, mammalian cells were har-
vested and rinsed with ice-cold HEPES-buffered saline
(pH 7.0), then lysed in an ice-cold cell lysis buffer [20 mMRetrovirology 2007, 4:16 http://www.retrovirology.com/content/4/1/16
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Tris-HCl, pH7.6, 150 mM NaCl, 1 mM EDTA, 0.5% Non-
idet P-40, 1 mM DTT, 5 μM Trichostatin A, 1 mM sodium
orthovanadate, 1 mM PMSF, 1 mM NaF and complete
protease inhibitors (Roche Applied Science)]. Cellular
lysates were prepared and the protein concentration was
determined using the Pierce protein assay kit. For immu-
noblotting, an aliquot of total lysate (50 μg of proteins) in
2× SDS-PAGE sample buffer (1:1 v/v) was electrophoresed
and transferred to a nitrocellulose filter. Filters were incu-
bated with appropriate primary antibody in Tris-buffered
saline (TBS, pH 7.5) and 5% skim milk or 5% BSA over-
night. After washing, the filter was incubated with second-
ary antibody in TBS-Tween-20 (TBS-T) buffer for 1 h.
Protein bands were visualized by an ECL detection sys-
tem.
For Western blot analysis of fission yeast proteins, cells
were washed once with water prior to adding cold stop
buffer (150 mM NaCl, 50 mM NaF, 10 mM EDTA, 1 mM
NaN3, pH 8.0). Cells were then collected by centrifugation
and resuspended in 3 volumes of HB buffer (25 mM
MOPS, pH7.2, 60 mM β-glycerophosphate, 15 mM p-
nitrophenyl phosphate, 15 mM MgCI2, 15 mM EGTA, 1%
Triton X-100, 1 mM DTT). A mixture of protease inhibi-
tors (1 mM PMSF, 20 μg/ml leupeptin, 40 μg/ml apro-
tinin and 0.1 mM sodium vanadate) and a commercial
complete mini protease inhibitor cocktail (Roche, one
tablet per 7 ml) was added immediately before lysis by
glass-bead agitation. The cells were disrupted for 60 sec
using a bead beater (Biospec Products, Bartlesville, OK).
Cell breakage was checked under the microscope and dis-
ruption was repeated 3–5 times if necessary. Protein con-
centration was measured using the BCA protein assay kit
(Pierce). Equal amounts of protein (30 μg) were resolved
on a SDS-polyacrylamide gel and transferred to a nitrocel-
lulose membrane. HIV-1 Vpr or Hsp16 protein levels were
assayed by immunoblotting procedures using anti-Vpr
serum (generated in our laboratory) and anti-Hsp16
serum (Paul Young's laboratory), respectively. Immunob-
lots were developed using the enhanced chemilumines-
cent (ECL) system (Pierce).
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